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our previously described protocol formapping pathogenicmutations in the human POLG gene to functional clus-
ters in the catalytic core of the mitochondrial replicase, Pol γ (1). We assigned 136mutations to ﬁve clusters and
identify segments of primary sequence that can be used to delimit the boundaries of each cluster.We report that
compound heterozygotes with two mutations from different clusters manifested more severe, earlier-onset
POLG syndromes, whereas two mutations from the same cluster are less common and generally are associated
with less severe, later onset POLG syndromes. We also show that speciﬁc cluster combinations are more severe
than others and have a higher likelihood tomanifest at an earlier age. Our clusteringmethod provides a powerful
tool to predict the pathogenic potential and predicted disease phenotype of novel variants and mutations in
POLG, the most common nuclear gene underlying mitochondrial disorders. We propose that such a prediction
tool would be useful for routine diagnostics for mitochondrial disorders. This article is part of a Special Issue
entitled: 18th European Bioenergetic Conference.
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Mitochondrial dysfunction due to impaired energy production via
oxidative phosphorylation (OXPHOS) causes a variety of diseases,
known collectively as mitochondrial disorders [2]. Base substitutions,
deletions or depletion of mitochondrial DNA (mtDNA) resulting in pro-
duction of dysfunctional and/or depletion of OXPHOS proteins is an im-
portant cause of mitochondrial dysfunction [2]. In animalmitochondria,
Pol γ is the only knownDNApolymerase, and therefore, it is responsible
for maintenance of mtDNA integrity associated withmtDNA replication
and repair [3]. Human Pol γ is a heterotrimer consisting of a catalytic
subunit, PolγA, and a dimer of an accessory subunit, PolγB [4]. Encoded
by the POLG gene, Pol γA, known as the catalytic core, is a 140-kDa poly-
peptide that contains the 5′–3′ DNA polymerase (pol), 3′–5′ exonucle-
ase (exo), and 5′-dRP lyase activities [3]. Mutations in the POLG gene
lead to the accumulation of mtDNA deletions as well as mtDNA deple-
tion, manifesting mitochondrial disorders termed POLG syndromes
[5]. The most severe form of POLG syndrome, known as Alpers syn-
drome, is caused by compound heterozygosity of two recessive POLGopean Bioenergetic Conference.
try and Molecular Biology, 603
824-6476.
ights reserved.mutations and leads to hepatocerebralmtDNAdepletion syndromedur-
ing infancy and death at an early age [6]. Late-onset POLG syndromes,
such as progressive external ophthalmoplegia (PEO), can be caused by
dominant or recessive compoundheterozygousmutations and are asso-
ciated with varying degrees of tissue-speciﬁc mtDNA depletion and/or
single or multiple mtDNA deletions [7].
The crystal structure of Pol γ was determined in its apoenzyme
form (PDB code 3IKM [8]). Its catalytic core has three major
domains: an N-terminal Exo domain that contains the exo active site,
a C-terminal Pol domain that contains the pol active site, and a spacer
domain that separates the Exo and Pol domains in primary sequence.
Three subdomains are deﬁned in the Pol domain: the palm subdomain
represents the most highly conserved structural module between
non-homologous DNA polymerases and contains the pol catalytic site
coordinating twoMg2+ ions, the ﬁngers subdomain is involved in bind-
ing the incoming dNTP substrate, and the thumb subdomain forms
a major surface of the DNA binding channel. The spacer domain
comprises two subdomains: the accessory interacting domain (AID),
which forms themajor hydrophobic contact with the proximal accesso-
ry subunit, and the intrinsic processivity (IP) domain, which forms a re-
gion of the upstream DNA binding channel and does not contact the
accessory subunits. Both subdomains form distinct regions of the up-
stream DNA binding channel, but the ﬂexible AID contributes to DNA
binding afﬁnity only when the accessory subunit stabilizes it in the cor-
rect position [9]. The extreme N-terminal residues of the catalytic core
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family A polymerase group and are thus designated as a sepa-
rate N-terminal domain (NTD), which presumably contains the
mitochondrial leader sequence.
Pol γ is a member of the family A polymerase group and shares the
highest sequence similarity with bacteriophage T7 DNA polymerase
(T7 Pol) [8]. We generated a structural model of the Pol γ ternary com-
plex by superimposing the apo-holoenzyme Pol γ structure (PDB code
3IKM) [1] with the structure of T7 DNA polymerase (PDB code 1T8E)
with bound primer template DNA, incoming ddNTP, and Mg2+ ions.
We then mapped 58 Alpers mutations onto this structural model and
reported that they cluster into distinct regions, which we termed clus-
ters 1–5 [1]. Because Pol γ is a family A polymerase, functional insight
can be extrapolated from the extensive studies of conserved elements
in bacterial DNA polymerase I (Pol I) and T7 Pol [10–15]. This and the
evaluation of the unique features of Pol γ by the biochemical analysis
of yeast,ﬂy, andhumanPolγ variants [16–18] revealed that each cluster
deﬁnes a unique functional region,which exhibits a distinct biochemical
defect when affected by a pathogenic mutation [1]. Cluster 1 mutations
are predicted to cause a primary defect in pol activity and affect residues
involved directly in catalysis or indirectly by affecting architectural res-
idues that may disrupt the position of catalytic residues. Catalytic resi-
dues include those binding the two Mg2+ ions, those that make
contact with the incoming dNTP, and those that make contact with
the ﬁrst, second and third nucleotide pairs in the nascent dsDNA,
which are critical for correct positioning of the substrate in thepol active
site. For example, the human pathogenic mutation R943H affects an
amino acid residue that contacts the γ phosphate of the incoming
dNTP and has been shown in vitro to have a 30-fold increase in Km for
dNTPs and a 5-fold decrease in kcat, which together reduce pol activity
150-fold without affecting DNA binding afﬁnity [19]. Cluster 2 muta-
tions are predicted to cause a primary defect in DNA binding afﬁnity
and affect residues of the IP and AID that form the upstream DNA bind-
ing channel, which enhance DNA binding afﬁnity via contacts with nu-
cleotides upstream of the third base pair of primer template. For
example, the biochemical analysis of recombinant ﬂy Pol γwith a triple
alanine substitution in amino acid residues K768/D769/F770, which are
located in the DNA binding channel wall of the IP domain, showed a
small decrease in binding afﬁnity [17]. Cluster 3mutations are predicted
to affect the pol:exo activity ratio andmay have variable defects in DNA
binding afﬁnity. Many of the cluster 3 mutations map to a helix–coil–
helix module (residues 295–312) located in the Exo domain that has
been termed the “orienter”module [18]. L304R of the “orienter”module
has been studied biochemically in recombinant yeast Pol γ and exhibits
3-fold increased exo activity, 20-fold decreased pol activity, and 10-fold
decreased DNA binding afﬁnity [18]. In addition, cluster 3 mutations
map to the partitioning loop, which is a novel module conserved in
Pol γ (residues 1050–1095) that is located between the ﬁngers and
the palm subdomains and is not present in any other known polymer-
ase [1]. To date, no biochemical data are available for residues of the
partitioning loop, although it has been shown that yeast strains homo-
zygous for a mutation that is equivalent to G1051R in human Pol γ
cause a 10-fold increase in pointmutational frequency in vivo [20]. Clus-
ter 4 mutations map to the Exo domain along the distal accessory sub-
unit interface and are predicted to cause a biochemical defect similar
to the R232G variant, which was shown in vitro to have reduced pol
rate, increased exo activity, and wild-type (WT) DNA binding afﬁnity
[21]. Cluster 5 mutations are located in the periphery of the IP
subdomain and have not been shown to cause a biochemical defect.
For example, human recombinant Pol γ harboring R627Q or R627W
mutations exhibited no defects in vitrowhen analyzed for DNA binding
afﬁnity, pol activity, and stimulation by the accessory subunit [22].
In applying our clustering model to the reported Alpers mutations,
we found that Alpers syndromewas found only in compound heterozy-
gous patients bearing twomutations from different clusters in Pol γ [1].
Since publication, several new reports have been published thathave added dozens of new mutations and mutation combinations
to the POLG syndrome library [23–26]. Here, we examine potential
genotype–phenotype correlations by analyzing all reported POLGmuta-
tions available to date, not restricted to a phenotype or age of onset, uti-
lizing our clusteringmodel. In total, we assign 136mutations to the ﬁve
clusters and identify segments of primary sequence that can be used to
delimit the boundaries of each cluster. We demonstrate the validity of
our clustering model as the ﬁrst to establish genotype–phenotype cor-
relations for POLG syndromes and show that it can be used to predict
the pathogenic potential and biochemical defects of novel mutations
and to provide information about the likely severity of the POLG
syndrome for compound heterozygotes with novel combinations of
mutations.
2. Methods
2.1. Computational analysis
We docked primer-template DNA (ptDNA) into the putative DNA-
binding channel of the Pol γ apo-holoenzyme crystal structure
(PDB code 3IKM [8]) by superimposing the closed ternary complex of
T7 Pol bound to ptDNA and dNTP (PDB code 1T8E [27]) using PyMOL
(http://www.pymol.org/). As we described previously, we found
that the best overall alignment was obtained by aligning the palm
subdomain of Pol γA (residues 815–910, 1095–1239) to the palm
subdomain of T7 Pol (residues 409–487, 611–704) [1]. This model was
used to map and evaluate all reported POLG disease mutations.
2.2. Statistical analysis
Weused Pearson's chi-square analysis to calculate the signiﬁcance of
each age of onset (infantile, childhood, juvenile, and adult) and themu-
tation combination affecting the same (=0) or different clusters (=1)
of Pol γ. Logistic regression analysis was used to calculate odds ratios
for having an infantile-onset disease. We conducted all statistical analy-
ses with Stata (version 11.0). Two-sided p values were used with a sig-
niﬁcance level of 0.05. We thank Dr. Kirsi Pietiläinen for help with the
statistical analysis.
3. Results
3.1. Cluster assignment of all reported POLG disease mutations
The Alpers mutations represent only a subset of the total library of
reported disease-causing mutations in POLG. To investigate further the
utility of the ﬁve functional clusters in Pol γ that we deﬁned earlier to
evaluate Alpers mutations [1], we compiled a list of all pathogenic
point mutations reported to date by combining the POLG database en-
tries (http://tools.niehs.nih.gov/polg/) with new data from recent re-
ports [23–26,28,29]. The list comprises a total of 136 pathogenic point
mutations, including both dominant and recessive mutations. We in-
cluded in our analysis POLG mutations that represented the only
disease-causing defect identiﬁed in the patient, exclusive of mutations
in other genes associatedwithmitochondrial dysfunction, and excluded
consideration of null mutations. By excluding patients with mutations
in multiple genes associated with mitochondrial dysfunction, a clear
link can be established between the functional defects in Pol γ and
the severity of disease manifestations. Furthermore, we considered a
pathogenic mutation to be dominant only if the family history demon-
strated a dominant mode of inheritance, leaving out potential de novo
mutations.
We mapped each of the pathogenic mutations onto our structural
model and assigned them to a cluster by evaluating them individually.
Although a cluster may contain residues that are distant in primary se-
quence, assignment was straightforward in most cases because each
cluster occupies a distinct structural region in the Pol γ tertiary
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ent clusters, and because we did not deﬁne explicitly the boundaries of
the structural regions for each cluster in our previous analysis, wemade
use of additional criteria for cluster assignment. To do so, we analyzed
each point mutation based on reported biochemical data to predict
the functional defect it would cause. In this way, cluster assignment is
based not only on structural location but also on functional insight. In
total, we assigned 136 pathogenic mutations to the ﬁve functional clus-
terswe deﬁned earlier [1], as shown in Fig. 1. Because of the large library
of reported mutations, we concluded that a sufﬁcient number of muta-
tionswere assigned to each cluster to use theirmap positions as the sole
means of deﬁning the structural region and primary sequence occupied
by each cluster. Mutations from each cluster are divided into several
subclusters of 10–100 amino acid residues and are distributed across
the length of the POLG gene (Fig. 1, upper schematic). Despite the
large separation of subclusters in primary sequence, the elements of a
cluster fold into compact structural regions as illustrated in Fig. 1
(lower panel).Fig. 1. Clustering of 136 pathogenicmutationswithin ﬁve functionalmodules in the catalytic sub
the clustering of 136 pathogenic mutations into discrete blocks of amino acid residues, which w
which they belong: cluster 1, green; cluster 2, yellow; cluster 3, red; cluster 4, blue; cluster 5, cya
911–1048), and thumb (Th, residues 440–475 and 785–814) subdomains of the Pol domain a
(subunit) interacting domain (AID, residues 476–570) and the intrinsic processivity (IP, residue
main (NTD, residues 1–170) and the Exo domain (residues 171–439) are colored in purple. Lo
docked primer template DNA shown as orange ribbon (for details, see Computational analysis se
structural elements (SSEs), with regions deﬁned by clusters illustrated as space-ﬁlledmodules,
as surface representations in light and dark gray, respectively.Sixty-eightmutationswere assigned to cluster 1, deﬁning seven sub-
clusters located in the NTD, Exo, and Pol domains. The primary bio-
chemical defect caused by a cluster 1 mutation is predicted to be
reduced pol activity. As expected, most mutations affect residues of
the Pol domain, including the ﬁve conserved motifs within the Pol do-
main of family A polymerases that are essential for 5′–3′ DNA polymer-
ase activity (Fig. 2, upper schematic [12]). Subcluster 1E (residues
914–966) spans the O-helix and its environs (Fig. 2, lower panel), the
function of which is to bind the correct dNTP substrate by transitioning
between an open and a closed complex [30]. The conserved amino acid
residues on the O-helix are known as the Pol B motif (residues
943–958), which establishes speciﬁc contactswith correctly base paired
dNTP in the closed conformation [12]. POLG mutations that disrupt the
speciﬁc contacts with the incoming dNTP (H932Y, R943H, K947R,
Y951N, andY955C)will reduceﬁdelity and increase Km (dNTP), without
affectingDNAbinding afﬁnity [19,31]. Thus,mutations affecting this site
are most likely dominant because they are capable of competing for
dNTP binding with wild-type (WT) Pol γ but are unable to polymerizeunit of human Pol γ. Upper panel: schematic diagram of the human POLG gene illustrating
e term subclusters. Mutant alleles and subclusters are colored according to the cluster to
n (see the text for details). The palm (residues 815–910 and 1096–1239), ﬁngers (residues
re colored pink, and the partitioning loop (PL, residues 1049–1095) is red. The accessory
s 571–784) subdomains of the spacer domain are colored inmagenta. The N-terminal do-
wer panel: structural model of the human Pol γ apo-holoenzyme (PDB code 3IKM) with
ction). The catalytic subunit of Pol γ is shown as a cartoon representation of the secondary
colored according to the schematic. The proximal and distal accessory subunits are shown
Fig. 2. Architectural and functional subclusters of the Pol domain. Upper panel: schematic diagram of the POLG gene as shown in Fig. 1, with an additional upper section indicating the
location of the three Exo motifs, labeled as I, II, and III, and the six Pol motifs, labeled as 1 (motif 1), 2 (motif 2), A (Pol A motif), B (Pol B motif), 6 (motif 6), and C (Pol C motif), which
are conserved throughout family A polymerases (see text).Motifs and subclusters that are illustrated in the bottompanels are in shown bold. Bottom panels: SSEs and transparent surface
representation of the palmandﬁngers subdomains of Polγ (PDB code3IKM) are shown(subdomains are colored ingray in themiddle section of the schematic). Bottom-left panel: theﬁve
motifs of the Pol domain, which are colored in pink in the upper section of the schematic, are shown as pink SSEs and are labeled accordingly. Docked primer template DNA is shown as
orange ribbon,Mg2+ ions are shown as orange spheres, and the incoming dNTP is shown as orange sticks (for details, see Computational analysis section). Bottom-right panel: subclusters
1D, 1E, and 1F encompass one ormore of theﬁve conservedmotifs of the Pol domain and are colored in light green. Subclusters 1A, 1B, 1C, and 1G, colored indark green, are located further
structurally from the pol active site, and are considered to play an architectural role.
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that is associated with enzyme stalling [32].
Subcluster 1D (residues 848–895) comprises the RR loop (residues
845–863) [1] and the conserved Pol A motif (residues 887–896) of the
palm subdomain (Fig. 2) [3]. The RR loop is equivalent to motif 2 in
Pol I and is critical for binding correctly base-paired ptDNA in the
minor groove and the template DNA backbone [12]. The Pol A motif in
Pol I contacts the primer strand, binds Mg2+ via amino acid residue
D705 (D890 in Pol γ) and discriminates against ribonucleotide incorpo-
ration via residue E710 (E895 in Polγ) [33]. Mutations in the Pol Amotif
at either D890 or E895 in Pol γwould likely manifest a dominant lethal
phenotype, and the only reported patient to date with the E895Gmuta-
tion died immediately after birth [34]. Motif 2 mutations should always
cause reduced pol activity but may also cause a DNA binding defect de-
pending on the residue, such as the 5-fold defect reported for G848S and
R852C [35]. The DNA binding afﬁnity of T851A, R853Q, Q879H, and
T885S may decrease slightly, but the reduction in pol activity is much
greater [35]. Overall, we feel it is unlikely for dominantmutations to re-
side in motif 2 because these mutant forms of Pol γwould not compete
with WT Pol γ for DNA binding.
Subcluster 1F (residues 1104–1138) comprises motif 6 (residues
1097–1110) and the Pol C motif (residues 1134–1141) in the palm
subdomain (Fig. 2) (according to the nomenclature deﬁned for Pol I
[12]). Motif 6 is located on the Q-helix and binds correctly base-paired
template strand and the ptDNA minor groove in Pol I via the residues
N845 and Q849 ([13], equivalent to N1098 and Q1102 in Pol γ,
respectively). The Pol C motif in Pol γ binds Mg2+ via D1135, whereas
H1134 and E1136 contact the primer strand. Subcluster 1G (residues
1157–1196) maps to a C-terminal region of the palm subdomain and
forms an anti-parallel beta strand adjacent to the Pol A motif. Only
K1191 is predicted to contact the primer terminus, whereas the rest of
subcluster 1G serves an architectural role [1]. Mutations affecting
motif 6 have been reported to cause DNA binding defects along with
pol defects in Pol I Klenow [13]. However, an alanine substitution at
the equivalent residue to Pol γ H1134 in Klenow (H881A) caused a de-
crease in kcat from 6- to 66-fold [13] but retained DNA binding afﬁnity,
suggesting that a mutation in H1134 might be dominant.We assigned mutations to subclusters 1D–G with high conﬁdence
because there is extensive biochemical data available for the Pol do-
main, in addition to the presence of the highly conserved amino acid se-
quence motifs. In contrast, a subcluster of seven mutations (R417T,
C418R, G426S, L428P, M430L, G431V, and S433C) was mapped to the
G-helix (Fig. 2, lower right panel), a structural element that had not
been studied previously. According to the current Exo domain assign-
ment of residues 170–440 by Lee et al. [8], this subcluster would reside
in the Exo domain, although earlier T7 Pol [15] and Pol I structures [36]
label the G-helix as part of the palm subdomain within the Pol domain.
Regardless of the domain assignment, this subcluster is adjacent to
motif 2 and motif 6, and we propose it serves an architectural role
that contributes to pol activity indirectly and assign it as subcluster 1C.
Four mutations from the NTD were also observed to be closer structur-
ally to functional Pol motifs as compared to Exo motifs; thus, we
assigned D136E and A143V as subcluster 1B (residues 136–143), and
both L83P and F88L were assigned as subcluster 1A (residues 83–88).
Twenty-ﬁvemutations fromcluster 2,whichwe predict to cause pri-
mary defects in DNA binding afﬁnity, outline the putative DNA binding
channel and map to four subclusters within the thumb subdomain of
the Pol domain (2A, residues 463–468) and the AID (2B, residues
497–517) and IP (2C, residues 561–617 and 2d, 752–767) subdomains
of the spacer domain. Subcluster 2C contains motif 1, which in Pol I
was shown to fold into a loop and binds DNA in the channel [12].
Motif 1 together with subcluster 2D forms the major face of the DNA
binding channel. Subcluster 2A maps to a region of the thumb
subdomain at the accessory subunit interface where A467T, N468D,
and L463F are positioned. Our group has characterized residue A467T
biochemically, and it was shown to retain 70% ofWTDNAbinding afﬁn-
ity in a reconstituted holoenzyme form [22]. The extensive biochemical
analysis of the spacer domain in general has demonstrated that the hy-
drophobic core of the IP subdomain is critical for shaping the DNA bind-
ing channel wall [17,22]. Mutations that alter the IP subdomain, such as
A467T, are predicted to perturb the channel to blockDNA fromentering,
which is then observed as reduced DNA binding afﬁnity.
Eightmutations from cluster 3map to the orientermodule [18,52] of
the Exo domain, and another 12 mutations from the same cluster map
Fig. 3. Analysis of mutation combinations as cluster combinations reveals predictive geno-
type–phenotype correlations. The data used to compile the information in this ﬁgure was
derived from the references included as Supplemental data. The number ofmutation com-
binations manifesting POLG syndrome at each of the four age groups is shown in each
panel for speciﬁc cluster combinations. Age of onset trends can be used to predict the se-
verity of POLG syndrome for an individual with compound heterozygous mutations in
POLG. Upper panel: POLG syndrome age of onset trends for mutation combinations of
two mutations from different clusters versus the same cluster. Middle panel: patient
data show trends in which severe cluster combinations have an earlier age of onset,
whereas less severe or uncommon cluster combinations have a later age of onset. Lower
panel: earlier age of onset trends for more severe cluster/subcluster combinations.
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subclusters (3B, residues 303–319 and 3D, 1047–1096, respectively).
Additionally, a recent report from the Foury group [37] has shown
that variants of yeast Pol γ bearing substitutions in residues of the
thumb subdomain M602I (R802 in Hs), and the Exo II motif of the Exo
domain A228V, R231K, and R233W (S272, R275, and H277 in Hs) also
produce the altered pol:exo activity ratio that characterizes cluster 3
mutations. Therefore, we assign pathogenic residues R807P, R807C,
R807H, and R804T as subcluster 3C (residues 804–807), and the Exo II
motif mutations G268A, R275Q, and H277L as subcluster 3A (residues
268–277). In support of the proposed subcluster 3C, we note that the
SYW triple alanine substitution in recombinant ﬂy Pol γ, which was
found to exhibit increased exo activity with both decreased pol activity
and DNA binding afﬁnity [17], maps adjacent to subcluster 3C in human
Pol γ (residues S799/F800/W801). Similarly, the Exo II motif has been
demonstrated to alter the pol:exo activity ratio in biochemical variants
of Pol I by decreasing the afﬁnity of the primer strand for the exo active
site, consistent with the decrease in exo activity andWT pol activity ob-
served for the R233Wvariant in yeast Pol γ (H277 in human Pol γ) [37].
Six mutations in cluster 4 (comprising residues 224–244), C224Y,
R227P, R227W, R232G, R232H, and L244P, map to a single region on
the subunit interface of the Exo domain. Biochemical studies of a
human R232G variant in reconstituted holoenzyme form showed a de-
crease in pol rate and an increase in exo activity, with unchanged DNA
binding afﬁnity that derive from loss of a direct stimulation of pol activ-
ity by the distal accessory subunit [21]. This, and an earlier study by Lee
et al. [53], support a distinct role for the distal accessory subunit in en-
hancing processivity. We propose that the other residues of cluster 4
have similar biochemical characteristics.
Ten mutations from cluster 5 are also located in the IP domain,
but they map to the distal region far removed from the DNA binding
channel and deﬁne subcluster 5A (residues 623–648) and subcluster
5B (residues 737–749).
3.2. Cluster assignment can be used to predict the pathogenicity of a novel
mutation
Our clusteringmodel provides an annotated guide to assign function
to the entire mutational spectrum in the POLG gene, and we propose
that it can be used to evaluate the potential pathogenicity of novel
POLGmutations. In particular, when a novelmutationmaps to a speciﬁc
subcluster within the ﬁve functional clusters we have deﬁned, we pre-
dict that it will likely be pathogenic and result in the biochemical defect
associated with that subcluster. At the same time, we would argue that
mutations that do not map to these speciﬁc amino acid sequence blocks
are more likely to be neutral polymorphisms. In support of this model,
we found that only 12 out of 87 reported single nucleotide polymor-
phisms (SNPs) from the human dbSNP database (http://www.ncbi.
nlm.nih.gov/projects/SNP/) map within subclusters (Fig. S1). Three of
these are conservative substitutions of highly similar amino acids
(F1092L, F1164L, and F1164I) and likely have no functional conse-
quences. These examples would suggest that although a mutation
may affect a residue within a functional subcluster, conservative substi-
tutions with amino acids with highly similar chemical properties may
not be pathogenic, and this possibility should be taken into consider-
ation when evaluating novel mutations. Additionally, missense muta-
tions reported as SNPs in the SNP database are not necessarily non-
pathogenic, as they could be uncommon recessive mutations that are
masked when paired with a wild-type allele.
Although the mutation library is large, the POLGmutational map is
likely not yet saturated, so routine sequencing of patients with POLG
syndrome will continue to ﬁll out the spectrum. We predict that most
novel mutations will map within our current clusters because they are
by deﬁnition “mutational hotspots,” and importantly, we observe from
their positions within the crystal structure that they encompass the
known functional motifs required for the biochemical activities ofPol γ. For example, based on the high sequence conservation with fam-
ily A polymerases, we note that the essential elements of the pol active
site such as the Pol A-C motifs, motif 2, and motif 6 are each populated
by human pathogenic mutations that map within our current cluster 1
(Figs. 1 and 2).3.3. Cluster combinations of compound heterozygotes correlate with age of
onset of POLG syndrome
Previously, we evaluated the combination of mutations in com-
pound heterozygotes that cause Alpers syndrome using our original
clustering model and found that Alpers was triggered exclusively by
the combination of two mutations from different clusters [1]. Here, we
evaluate all mutations causing POLG syndromes (caused by compound
heterozygosity) using the model reﬁned by the designation of subclus-
ters within the original ﬁve functional clusters. Although clinical
presentation and age of onset are extremely variable for POLG syn-
dromes, the severity of symptoms in general decreases with increasing
age of onset [38]. We were able to catalogue a total of 340 compound
heterozygous patients harboring two pathogenic mutations, and we
classiﬁed each patient by the age of onset reported. Each combination
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hood, ages 3–12 years; juvenile, 13–20 years; and adult, N20 years.
The data are compiled and evaluated in Fig. 3. Compound heterozygous
patients with two mutations from the same cluster were less common
(113/340) and were generally associated with late-onset POLG
syndromes (Fig. 3, upper panel). Compound heterozygous patients
with two mutations from different clusters were much more common
(227/340) and comprised 110/120 of the infantile-onset combinations.
These results argue that the combination of mutations from two differ-
ent clusters is not just a speciﬁc trigger for Alpers syndrome; rather, in
123 uniquemutation combinations in 227 compound heterozygous pa-
tients, it serves to represent a universal genotype–phenotype correla-
tion for all POLG syndromes.
3.4. Critical functions: clusters 1, 3, and 4
We predict that mutations affecting cluster 1 will reduce primarily
pol activity, and these have been associated with increased replication
fork stalling in vivo [32,52,53]. The stalling phenotype is characterized
by slow progression of or suspended replication forks and causes an ac-
cumulation of replication intermediates that can lead to double-
stranded DNA breaks, mtDNA deletions, and base substitution muta-
tions [39–41]. It is thus unlikely that a compound heterozygote with
two cluster 1 mutations would be viable unless the defects are very
mild. Indeed, only 11 such combinations of 14 different mutations
have been reported in 18 patients (Fig. S2) and involve mutations
such as G923D and A957S that retain 25% WT pol [19], which is a rela-
tively mild pol defect compared to other cluster 1 mutations, such as
the 100-fold reduction of pol activity engendered by the Y955C muta-
tion [32]. Although the partitioning loop has not been studied biochem-
ically, cluster 3 mutations may produce a biochemical phenotype
similar to that of the L260R variant in yeast Pol γ (L304R in Hs Pol γ),
which is characterized by an increase in exo activity and decreases in
pol activity and DNA binding afﬁnity [18]. Only four combinations
have been reported in 12 patients for compound heterozygotes with
two cluster 3 mutations (Fig. S2), which may indicate that most of
these combinations are lethal. Cluster 4 mutations are predicted to in-
crease exo activity and decrease pol rate, while retainingWT DNA bind-
ing afﬁnity [21]. Interestingly, cluster 4 mutations have not been
reported in combination with other cluster 4 mutations, or together
with cluster 3 mutations. When Pol γ is stalled, the primer strand can
translocate between the exo active site and the pol active site, a mode
described by Atanassova et al. [32] as idling. We speculate that cluster
3 and 4 mutants may manifest an idling phenotype because of their
enhanced exo:pol activity ratios, which is likely to increase non-
productive turnover by mutant Pol γ, via exonucleolytic hydrolysis of
correctly incorporated nucleotides. In compound heterozygotes, two
idling Pol γs may be lethal, explaining the absence of cluster 3+4 com-
binations aswell as cluster 4+4 combinations. Taken together, the lack
of complementation observed for clusters 1, 3, and 4 suggests that they
serve essential functions in mtDNA metabolism.
3.5. Moderately severe dysfunction: clusters 2 and 5
Mutations affecting cluster 2 will most likely cause a primary defect
in DNA binding afﬁnity. Processivity, deﬁned as the number of nucleo-
tides incorporated in a single DNA binding event, varies directly with
pol rate and DNA binding afﬁnity, and as a consequence, cluster 2muta-
tions reduce processivity. Individuals carrying homozygous A467T mu-
tations present as juveniles with POLG syndrome [26,42,43]. As we
showed that Polγ carrying theA467T substitution shows aDNAbinding
afﬁnity 70% of that ofWT [22], this suggests thatmoderate reductions in
DNA binding and pol activity may be tolerated throughout childhood. It
thus seems likely that most same cluster combinations of cluster 2
mutations will not be lethal and instead will lead to development of
later-onset POLG syndrome. Consistent with this hypothesis, 42 suchcombinations have been reported, and the majority show juvenile or
adult onset (Fig. 3, middle panel).
We have studied three cluster 5 mutations, W748S, R627Q, and
R627W, in the reconstituted human Pol γ holoenzyme, but all three re-
vealed no biochemical phenotype in our hands [22,44]. Thesemutations
map to the distal surface of the IP domain, far removed from the DNA
binding channel. Despite the lack of a documented biochemical pheno-
type, cluster 5 mutations have been reported in 139 compound hetero-
zygous patientswith POLG syndromemanifesting at all ages (Figs. 3 and
S2). Therefore, this region clearly carries a biologically relevant function
in mtDNAmetabolism because cluster 5 mutations cause mtDNA insta-
bility [44,45]. As for cluster 2 mutations, cluster 5 mutations are found
together in compound heterozygote individuals with juvenile- or
adult-onset POLG syndrome. Compound heterozygotes with a cluster
2 mutation and a cluster 5 mutation have been reported in 40 patients,
and a majority of the combinations resulted in juvenile- or adult-onset
POLG syndrome (Fig. 3,middle panel). Notably, this cluster combination
is the only one that did not typically cause infantile- or childhood-onset
POLG syndromes. To this point, 39/39 patients that were homozygous
for W748S only developed a mild adult-onset POLG syndrome
[46–48]. In sum, cluster 2 and cluster 5 mutations, in contrast to those
in clusters 1, 3, and 4, are observed to complement each other, perhaps
suggesting that individual amino acid residues within these clusters
serve less critical functions in mtDNA metabolism.3.6. Severe combination: cluster 1 + 2
Compound heterozygotes with cluster 1 and cluster 2 mutations
have been reported in 70 patients and are the most abundant of all
cluster combinations (Fig. 3, middle and lower panels). The majority
(44/70) of these combinations caused infantile-onset POLG syn-
drome. In fact, the most severe combinations observed in this study
are the subcluster combinations 1D+ 2A and 1E+ 2A. These combi-
nations cause infantile-onset POLG syndrome in 17/18 and 19/20
cases, respectively. Cluster 1 mutants have reduced pol activity but
will compete for DNA binding and cause enzyme stalling when
bound. Cluster 2 mutations show reduced DNA binding afﬁnity and
would be unable to compete for DNA binding with a cluster 1 mu-
tant. We predict this would result in more stalled enzyme complexes
than for bound cluster 2 complexes alone. Because cluster 2 mutants
show only modest decreases in pol activity, mtDNA depletion will
progress gradually until a threshold level is reached to give rise to
symptoms of POLG syndrome.
The two most common cluster 2 mutations are A467T and P587L,
and the latter is always reported in ciswith T251I in patients. The occur-
rence of twomutations together suggests either a genetic founder effect
(as in Hakonen et al. [46]) or a synergic or compensatory effect of the
variants. T251I maps to the Exo domain, but we consider it to be a
SNP for the following reasons: T251 is not a conserved amino acid, is
located on the protein surface, and is not in a reasonable proximity to
any functional region. In contrast, P587L is conserved in mammals
and ﬂy and is positioned in the putative DNA binding channel, and
two pathogenic mutations, G588D and P589L, are located directly adja-
cent to P587 on the same hairpin. By considering T251I as a SNP and ex-
cluding it from the functional analysis, P587L can be compared directly
to A467T for its relative pathogenicity. Although no mechanistic data
are available for POLG carrying the P587L allele, we suggest it will re-
duce DNA binding afﬁnity to a much lesser extent than A467T. A direct
comparison of the two mutations is possible in two different cluster 1
mutations. One patient was reported as compound heterozygous for
G848S/A467Twith infantile onset POLG syndrome [43], whereas anoth-
er was reported as compound heterozygous for G848S/P587L with
adult onset POLG syndrome [26]. Homozygosity for P587L + T251I re-
sults in a late-onset myopathy phenotype [7]. The same pattern is ob-
served with K1191N [7,26].
Fig. 4. Age of onset correlation for reported symptoms. Symptoms associated with POLG
syndromes manifest typically at different ages. The symptoms reported in the patients
have been grouped together based on affected tissue types and ordered according to
their ages of onset. The more severe symptoms and forms of POLG syndromes are at the
left end of the ﬁgure, while the less severe symptoms are at the right end. Detailed infor-
mation of the symptom grouping is shown in Table S1.
Fig. 5. Symptoms associated with different POLG syndromes. Depending on the speciﬁc
mutations and cluster combinations of the POLG gene mutations in individual patients,
POLG syndromes can become symptomatic at different ages and manifest as pathogenic
conditions in different tissue types. The ﬁgure shows a continuing spectrum of decreasing
symptom severity from top to bottom as well as a delayed age of onset from left to right.
MCHS, childhoodmyocerebrohepatopathy spectrum;MEMSA, myoclonic epilepsymyop-
athy sensory ataxia; ANS, autonomic nervous system dysfunction; arPEO/adPEO, autoso-
mal recessive/dominant progressive external ophthalmoplegia.
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Compound heterozygotes with cluster 1 and cluster 5 mutations
were reported showing that 23/42 mutation combinations had
infantile-onset POLG syndrome (Fig. 3, middle panel). Such a high oc-
currence of the most severe form of POLG syndrome, together with
the relatively large number of combinations documented, indicates
that the combined defects from cluster 1 and cluster 5 are highly
prone to cause mtDNA depletion at a young age. In particular, the
most common cluster 5 mutation, W748S, manifested infantile-onset
POLG syndrome in 28/31 patients when found in combination with
cluster 1 mutations. Two particularly severe combinations are the sub-
cluster combinations 1D + 5B and 1E + 5B; both result in infantile-
onset POLG syndrome in N80% of affected patients (Fig. 3, lower panel).
3.8. Other combinations
Cluster 4mutationswere reported in a total of 17 combinationswith
cluster 1 and cluster 2 (Fig. 3, lower panel). The incidence of infantile-
onset POLG syndrome was high (15/17) and may indicate that bio-
chemical defects of cluster 4 mutations are uniquely severe in vivo.
Infantile-onset POLG syndrome was less common for compound
heterozygotes with cluster 3 mutations in combination with cluster 1
(9/17), cluster 2 (10/22), and cluster 5 (3/12) (Fig. S2). These results
suggest that cluster 4 mutations are more pathogenic than cluster 3
mutations.
3.9. Expected incidence of speciﬁc symptoms caused by POLG syndrome can
be predicted by the age of onset
The clinical manifestations reported for each compound heterozy-
gous patientwere compiled in an effort to study the incidence and time-
line of symptoms caused by POLG syndrome. To analyze the clinical
descriptions in terms of individual symptoms, it was necessary to
group similar and synonymous symptoms into symptom groups
(Table S1). Very common symptoms, such as ataxia, seizures, hypotonia,
and migraines, were left as individual entries because their sample size
was sufﬁciently large, and these symptoms have been established as
hallmarks for speciﬁc POLG syndromes. For other symptom groups, it
was necessary to combine different symptoms into a group of related
symptoms based on the affected tissue type resulting in the observed
symptom. For example, the CPEO group includes all synonyms for
ophthalmoplegia as well as diplopia and ptosis, two symptoms that
both indicate impaired function of the extraocular muscles. Neurologi-
cal disorders are divided into two subcategories: the neuropathy
group includes symptoms caused by damage to peripheral neurons,
and the CNS group includes symptoms caused by damage to neurons
of the central nervous system. The developmental delay group includes
symptoms related to an encephalopathy that involve an altered mental
state. The myopathy, hepatopathy, and GI groups involve symptoms
that affect or are an indicator of dysfunction in muscle tissue, liver, or
gastrointestinal tract, respectively. Fig. 4 shows the incidence of each
symptom group in patients as a function of age of onset. The more se-
vere symptoms, such as hepatopathy, hypotonia, and developmental
delay have a high incidence among patients with infantile-onset POLG
syndrome, whereas less severe symptoms such as CPEOmanifest main-
ly in patientswith adult-onset POLG syndrome. These data demonstrate
that the symptoms caused by POLG syndromes represent a continuum
of manifestations that become less severe as the age of onset increases.
These syndromes have been characterized in the past according to spe-
ciﬁc groups of co-occurring symptoms that present in patients. For ex-
ample, Alpers syndrome is characterized by seizures, developmental
delay, and liver failure. Fig. 5 displays the timeline of POLG syndromes
and outlines the co-occurring symptoms that deﬁne each of the speciﬁc
syndromes that have been used to characterize patients with pathogen-
ic POLGmutations.4. Discussion
Due to the mutational diversity in the POLG gene and the variable
clinical features of POLG syndromes, the establishment of genotype–
phenotype correlations has remained elusive [49]. Furthermore, a num-
ber of de novo variants emerge in routine diagnosis laboratories, and the
interpretation of their pathogenic role is challenging. We show here
that detailed protein structural and functional studies, with the aid of
a crystal structure, combined with knowledge from experimental and
disease mutations can be combined to predict clinical consequences of
an identiﬁed variant and to distinguish likely pathogenic mutations
from polymorphic variants. In this report, we demonstrate clear
genotype–phenotype correlations for predicting the severity and,
hence, the age of onset of compound heterozygous POLG syndromes.
1120 G.A. Farnum et al. / Biochimica et Biophysica Acta 1837 (2014) 1113–1121We reﬁne our clustering model of Pol γ [1], proposing ﬁve functional
clusters, each of which comprise subclusters that deﬁne structural
regions of the catalytic core of Pol γ. Within these clusters, we can
predict the likely biochemical defects and intrinsic pathogenicity of
novel point mutations. In applying this clustering protocol to nearly
140 combinations of POLG compound heterozygous mutations, we
showed that each cluster combination can be used to give informa-
tion of the potential severity of disease outcome. Strikingly, we
were able to predict correctly the age of onset in 90% of infantile-
onset POLG syndromes via the presence of two POLG mutations
from different clusters in compound heterozygotes. Furthermore,
we show that age of onset can be used to predict the symptoms
that a patient will manifest and provide a timeline of the disease
progression that may be expected.
Individuals carryingmutations in POLG canmanifest a disease at any
age, depending on the mutation combination as well as the severity of
the Pol γ functional defects [5,26,50]. Presumably, the most severe Pol
γ mutations would be embryonic lethal in compound heterozygous
formwith any other, even slightly deleterious mutation, and we specu-
late that they may also have the potential to be dominant. This is likely
the reason, for example, that nucleotide changes that yield amino acid
substitutions in the Mg2+ binding residues D890 and D1135 have
never been reported.We found a similar trend in our clustering analysis
showing a lower occurrence of compound heterozygotes from the same
cluster for clusters 1, 3, and 4. The low occurrence of same-cluster com-
pound heterozygotesmay indicate that themajority of potential combi-
nations of this type are lethal, and the lack of complementation supports
our assignment of a common biochemical defect. This does not, howev-
er, apply to IP-domain mutations, which as homozygous are a common
cause of severe progressive disorder that has a later disease onset in ju-
venile age or early adulthood. Therefore, combinations of mutations
that cause themost severe formof the POLG syndromeallow embryonic
development but lead to early infantile death.
We believe that our clusteringmodel of POLGmutations can be used
as a tool to aid in the diagnosis of patients withmitochondrial disorders.
The POLG gene shows considerable variation, and novel polymorphic
changes are common. A valuable existing tool, the polymerase gamma
database (http://tools.niehs.nih.gov/polg/), lists reported mutations,
but their pathogenic role sometimes remains unclear, especially for
rare changes. Our prediction tool adds considerable power via structural
analysis for the interpretation of the consequences of identiﬁed rare
variants and can provide information for novel changes. Furthermore,
it predicts the combinatorial effect of compound heterozygous changes
for a patient and provides information of typical clinical manifestations
and ages of onset.We note that these predictionsmay not always be ac-
curate, both because of the variability in disease manifestation intro-
duced by genetic background, and the possibility that a number of the
patients reported with POLG syndrome may also have other inherited
mutations in their mitochondrial or nuclear DNAs in addition to the re-
portedmutations in the POLG gene. Althoughwe excluded known cases
of digenic mitochondrial diseases in this study, the latter possibility re-
mains problematic and would be addressed by whole exome sequenc-
ing. Despite these potential drawbacks, we believe that our clustering
protocol provides additional information that will prove important
not only for diagnosis and genetic counseling but also for treatment;
e.g., the epilepsy drug valproate is toxic to the liver of patients with
POLGmutations [51], and as epilepsy is a common initial symptom in
children with POLG diseases, many patients have died before receiving
a liver transplant. The ability to predict pathogenic likelihood for new
POLG variants will be important when considering valproate as a treat-
ment in severe epilepsies. Finally, because the predictions are based on
reported patient data, the ever-increasing number of documented POLG
mutations will serve to enhance the diagnostic power of the clustering
protocol.
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